Steven A. Kaplan, M.D.

Urology

Publications

Peer Reviewed Publications   (Total 515)

 

1.          Kaplan SA: Double lumen Hickman catheters in long term dialysis. Kidney International, 19:47 - 51, 1983.

 

2.          Shanzer H, Kaplan S: Double lumen silicone rubber indwelling venous catheters. Archives of Surgery, 121, 89-94, 1986.

 

3.          Kaplan SA, Shanzer H, Racelli D, et al: Orthotopic, segmental small bowel transplantation in the rat. Mount Sinai Journal of Medicine, 53: 112-116, 1986.

 

4.          Benson MC, Kaplan SA, Olsson CA: Prostate cancer in men under the age of 45. Journal of Urology, 137:888 - 890, 1987.

 

5.          Kaplan SA, Karp F, Benson MC: Use of a DNA index and mean channel number to identify subtle degrees of aneuploidy. Cytometry, 45:37 - 44, 1987. 

 

6.          Kaplan SA, Benson MC: Mean channel number versus modal channel number in flow cytometric   analysis. Journal of Urology, 139: 322 - 327, 1988.

 

7.          Kaplan SA, Blaivas JG: A practical approach to the diagnosis of urinary incontinence. Seminars in   Neurology 53:139-142, 1988

 

8.          Blaivas JG, Kaplan SA: Urological dysfunction in patients with multiple sclerosis. Seminars in Neurology- 51: 325-230, 1988. 

 

9.          Kaplan SA, Blaivas JG: Lower urinary tract manifestations in diabetes mellitus. Journal of Diabetic Complications. 3:15 - 19, 1988

 

10.       Kaplan SA, Sawczuk IS, Olsson CA: Contemporary cystectomy versus preoperative radiotherapy and cystectomy for invasive bladder cancer. Urology 38: 67 - 71, 1988.           

 

11.       Kaplan SA, Brown WC, Blaivas JG: Parameters of detrusor contractility: Effects of hysteresis and bladder volume in an in‑vitro whole rabbit model. Surgical Forum 40: 665‑666, 1989.

 

12.       Kaplan SA, Blaivas JG, Brown WC, Schuessler GB: Parameters of detrusor contractility: I: The effect of bladder volume and outlet resistance on Qmax, power and work in an in‑vitro whole rabbit model. Neurourology Urodynamics 8(4):375‑376, 1989.

 

13.       Kaplan SA, Brown WC, Chancellor MB, Schuessler GB, Blaivas JG: Parameters of detrusor contractility: II: The effect of outlet resistance on the mechanical indices: power, work and Wf. J Urol 143:354 - 357, 1990.

 

14.       Kaplan SA, Blaivas JG: Management of bladder problems of the MS patient. Journal of Enterostomal Therapy, 13:16 - 20, 1990.

 

15.       Kaplan SA, Brown WC, Levin RM, Blaivas JG: Parameters of detrusor contractility: I: The effect of hysteresis, electrical stimulation and bladder volume in an in‑vitro whole rabbit model.   Neurourology and Urodynamics. 10:53 - 57, 1991.

 

16.       Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S: Bladder outlet obstruction versus impaired detrusor contractility: the role of uroflow. J. Urol, 145:810 - 814, 1991

 

17.       Kaplan SA, Chancellor MB, Blaivas JG: Bladder and sphincter behavior in patients with spinal cord injury. J. Urol. 146:113 - 117, 1991.

 

18.       Koo HP, Buttyan R, Olsson CA and Kaplan SA: Genetic response of the rat bladder during the onset of streptozotocin induced diabetic cystopathy.  Surgical Forum, 42:36 - 41, 1991.

 

19.       Kaplan SA, Shabsigh R, Soldo KA and Olsson CA: Prostatic and Periprostatic Interstitial Temperature Measurements During Transrectal Hyperthermia. J Urol, 147:1562 - 1565, 1992.

 

20.       Kaplan SA, Kohn I, Amis S, O'Toole K, Bixon R and Giella J: Renal angiomyolipoma presenting as a retroperitoneal hemorrhage after thrombolytic therapy for acute myocardial infarction. N.Y. State J. Med. 92 (5)17 - 20, 1992.

 

21.         Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostatic specific antigen: Means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol, 147(3):815 - 819, 1992.

 

22.         Kaplan SA, Benson MC: Arterio‑venous malformation of the ureter. Urology, 40(5):450-2, 1992.

 

23.         Chancellor MB, Kaplan SA, Blaivas JG: A new method of measuring uroflow in the rat bladder. Neurourology and Urodynamics. 11:(2) 123 - 129, 1992. 

 

24.         Kaplan SA, Blaivas JG: Neurophysiology of storage and voiding function. Current Opinion in Urology, 2(4):248-251, 1992.

 

25.         Te AE, Buttyan R, Koo HP, Olsson CA, Kaplan SA : Nerve growth factors in diabetic cystopathy Neurourol & Urodynam 11:4:303-304. 1992.

 

26.         Chancellor MB, Kaplan SA, Blaivas JG: The cholinergic and purinergic components of detrusor contractility in a whole rabbit bladder model. J Urol,148:906-909, 1992

 

27.         Koo HP, Buttyan R, Olsson CA, Shabsigh R and Kaplan SA: Early molecular changes associated   with streptozotocin-induced diabetic bladder hypertrophy in the rat. Urol Res 1993: 21 (6):375-81.

 

28.         Kaplan SA, Shabsigh R, Soldo KA, Blaivas JG and Olsson CA: Applicator-urethral distance as a predictor of response after transrectal thermal therapy. Br. J. Urol 72 (2): 195-200, 1993.

 

29.         Kaplan SA, Soldo KA, Olsson CA: Daytime versus nighttime dosing of the long acting alpha blockers, terazosin and doxazosin. Urology 42:129 - 132, 1993.

 

30.         Walton GR, Kaplan SA : Urinary dysfunction in tropical spastic paraparesis: preliminary urodynamic survey. J Urol. 150 (3): 930-2, 1993.

 

31.         Kaplan SA, Merrill DC, Benson RC, Jr, Fuselier HA, Moseley WG, Parra R: The titan intra-prostatic stent: the early United States experience. J Urol, November, 150:1198- 201, 1993.

 

32.         Santarosa R, Colombel M, Kaplan SA, Monson F, Levin R, Buttyan R: Regression of the hypertrophied rabbit bladder involves extensive apoptosis of cells in the urothelium and serosal lamnia. Laboratory Investigation, 70:503 - 510, 1994.

 

33.         Kaplan SA, Koo HP: Benign prostatic hyperplasia. Compr Ther 19(1):21-4, 1993.

 

34.         Kaplan SA and Olsson CA: Microwave therapy in the management of men with BPH: current status.   J. Urol Nov; 150 (5) Pt 2): 1597-602, 1993.S

 

35.         Seaman EK, Jacobs BZ, Blaivas JG, Kaplan SA : Persistence or recurrence of symptoms after   TURP: A urodynamic assessment. J. Urol Sep: 152 (2) 935-7, 1994.

 

36.         Kaplan SA, Soldo KA and Olsson CA: Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism. Urol Sep 44(3):348:52,   1994.

 

37.         Te A, Buttyan R, Greene L, Kaplan SA, Koo HP, Olsson CA, Shabsigh R: Neurotrophins in the rat penis I: A developmental study. J Urol 152 (6): 2167 -72, 1994.

 

38.         Kaplan SA, Te AE and Jacobs BZ: Urodynamic evidence of vesical neck obstruction in men with   "chronic non-bacterial" prostatitis and the therapeutic role of endoscopic incision of the bladder neck. J. Urol 152 (6):2063-5, 1994.

 

39.         Oesterling JE, Kaplan SA, Epstein HB, DeFalco AF and the North American Experience with the Urolume Endoprosthesis as a treatment for benign prostatic hyperplasia: Long term results. Urology 44 (3): 353-62, 1994.

40.         Kaplan SA, Te AE, Blaivas JG: Urodynamic findings in diabetic cystopathy: Surprising results. J. Urol. 153 (2):342-4, 1995.

 

41.         Goluboff E, Chang D, Olsson CA, Kaplan SA : Urodynamics and the etiology of post -

             prostatectomy incontinence. J Urol 153 (3): 1034-7, 1995.

 

42.         Kaplan SA, Goluboff E, Soldo KA, Olsson CA, Dverka PD: Patient choice for symptomatic prostatism. Urology, 45:398, 1995.

 

43.         Kaplan SA, Soldo KA, Olsson CA: Terazosin and doxazosin in normotensive men with

symptomatic prostatism: effect of dosing regimen on efficacy and safety. Euro    Urol 28 (3) 223-8, 1995.

 

44.         Kaplan SA, Chiou RK, Morton WJ, Katz PG and The North American TITAN Stent study group. Urology 45 (2):234-40, 1995.

 

45.         Kaplan SA, Goluboff ET, Olsson CA, Deverka PA. Chmiel JJ: Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urol 45 (3) :398-405, 1995.

 

46.         Goluboff E, Kaplan SA, Fisch HF: Seminal Vesicle Urinary Reflux as a Complication of Transurethral Resection of the Ejaculatory Ducts. J. Urol 153 (4) 1223-5, 1995.

 

47.         Kaplan SA, Greenberg R, Baust J: A comparative assessment of cryosurgical devices: application to prostatic disease. Urol 1995 45 (4): 692-9, 1995.

 

48.         Kaplan SA  and Te AE: Uroflowmetry and Multichannel Urodynamics. Urol Clin N Amer 22 (2): 309-20, 1995.

 

49.         Te AE and Kaplan SA: Transurethral electrovaporization of the prostate (TVP): A novel method of treating men with benign prostatic hyperplasia. Urol 45 (4):566-72, 1995.

 

50.         Brisman JL, Kirsch AJ, Taylor JA, Birch BD, Hibshoosh HH and Kaplan SA : Pulmonary lmphangiomyomatosis in tuberous sclerosis: association with chronic renal failure: Case report and review of the literature. P & S Med Rev, 2:17, 1994.

 

51.         Kaplan SA, and Te AE: Transurethral electrovaporization of the prostate (TVP): An electrosurgical modification of TURP. Curr Surg Techn 8 (1): 1-8, 1995.

 

52.         Kaplan SA, and Te AE: A comparative study of transurethral resection of the prostate using a modified electrovaporizing loop and transurethral laser vaporization of the prostate. J Urol 154 (5): 1785-90, 1995.

 

53.       Kaplan SA, Te AE, Pressler LB and Olsson CA: Transition zone index (TZI), a novel method of assessing benign prostatic hyperplasia: correlation with symptoms, uroflow and detrusor pressure. J Urol 154 (5): 1764-9, 1995.

 

54.       Kaplan SA, Meade - D’alisera P, Quinones S and Soldo K: Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia: a study of safety and efficacy. Urol 46 (4) 512-7, 1995.

 

55.       Kaplan SA,   Bowers DL, Te AE and Olsson CA: The differential diagnosis of prostatism: a 12 year retrospective analysis of symptoms, urodynamics and satisfaction this therapy. J Urol 155 (4):1305-8, 1996.

 

56.       Roehrborn C, Oesterling JE, Auerbach S, Kaplan SA, and the HYCAT Study Group: Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic   benign prostatic hyperplasia in the HYCAT study. Urology 47 (2): 159-68, 1996.

 

57.       Kaplan SA and Olsson CA: Patient satisfaction with finasteride for the treatment of symptomatic benign prostatic hyperplasia. Clin Ther 18 (1): 73-83, 1996.

 

58.       Te AE and Kaplan SA: Electrovaporization of the prostate. Current Opinion in Urology. 6(1) 3 - 9, 1996.

 

59.       Kaplan SA, Olsson CA, Te AE: The AHCPR guidelines in the evaluation of men with lower urinary tract symptoms: at 2 years follow - up, does it work? J Urol 155(6): 1971-4, 1996.

 

60.       Kaplan SA:   Doxazosin in the elderly male patient with hypertension and BPH. Eur Urol. 29: 178 - 181, 1996.

 

61.       Kaplan SA, Ikeguchi EF, Santarosa RP, D’Alisera PM, Hendricks J, Te AE and Miller M: Etiology of voiding dysfunction in men < 50 years of age. Urol 47 (6): 836-9, 1996.

 

62.       Reis RB and Kaplan SA : Significant correlation of the AUA symptom score and a novel urodynamic parameter: detrusor contraction duration. J Urol. 156:1668 - 1672, 1996.

 

63.       Kaplan SA and Santarosa RP, Te AE: Comparison of fascial and vaginal wall slings in the management of intrinsic sphincter deficiency. Urol 47 (6): 885-9, 1996.

 

64.       Te AE, Santarosa R, Kaplan SA: Electrovaporization of the prostate: an electrosurgical modification of the standard TURP in 93 patients with BPH. J Endourol 10: 65 - 69, 1996.

 

65.       Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K, Dias N, for the Multicenter Study Group: Doxazosin in benign prostatic hyperplasia: long term efficacy and safety in hypertensive and normotensive patients. J. Urol 57 (2):525-30, 1997.

 

66.       Santarosa RP and Kaplan SA: Stress urinary incontinence in women. Brazilian J Urol 13:329 - 337, 1996. 

 

67.       Kaplan SA and Kaplan NM: Alpha blockade as a monotherapy for both hypertension and BPH. Urol 48 (4): 541-50, 1996.

 

68.       McKiernan J, Kaplan SA, Te AE, Santarosa RP and Sawczuk IS: Transurethral electrovaporization of   bladder tumors. Urol 48 (2):207-10, 1996.

 

69.       Kaplan SA: BPH: Are we too hot for new therapies? J Urol 156 (2 Pt 1):426-7, 1996.

 

70.       Kaplan SA, Santarosa RP and Te AE: Transurethral electrovaporization of the prostate: one year experience. Urol 48 (6):876-81., 1996.

 

71.       Kaplan SA: Electrovaporization of the prostate: durable modality or passing fad? Urol 49 (2): 157-9, 1997.

 

72.       Klein LT and Kaplan SA: Prostatic stents for benign prostatic hyperplasia. J Long Term Complications of Med Implants. J Long Term Compl 7(1): 101- 114, 1997.

 

73.       Kaplan SA, Santarosa RP, D’Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, Klein L, Te AE: “Pseudo” dyssynergia (contraction of the external sphincter during voiding) misdiagnosed as     “chronic non - bacterial prostatitis” and the role of biofeedback as a therapeutic option. J Urol. 157:897 - 901, 1997. 

 

74.       Kaplan SA, Meade D’Alisera P: Tolerability of alpha blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double - blind placebo - controlled studies. Am J Ger 53A(3):M201 – M206, 1998.

 

75.       Kaplan SA, Te AE, Ikeguchi E, Santarosa RP: Safety and efficacy of alpha blockers in the treatment of men over the age of 80 with benign prostatic hyperplasia. British Journal of Urology. 1999

 

76.       Mobley D, Kaplan SA, Ice K, Gaffney and Dias N: Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double - blind placebo - controlled studies. Int J Clin Prac. 51(5), 1997.

 

77.       Sandler P, Avillo C, Kaplan SA: Detrusor areflexia in a patient with myasthenia gravis. Int J Urol. 5(2): 188 – 190, 1998.

 

78.       Kaplan SA, Laor E, Fatal M, Te AE: Transurethral resection of the prostate (TURP) versus transurethral electrovaporization of the prostate (TVP): a blinded, prospective comparative study with 1 year follow - up. J. Urol. February, 1998.

 

79.       Kaplan SA, Kohn IJ, Te AE and Reis RB: Intermittent alpha blocker therapy in the treatment of men with lower urinary tract symptoms. Urology, 52:1, 1998.

 

80.       Shabsigh R, Klein L, Seidman S, Kaplan SA, Lehroff B, Ritter J: Increased incidence of depressive symptoms in men with erectile dysfunction. Urology, 52(5): 848 – 852, 1998.

 

81.       Kaplan SA: Minimally invasive alternative therapeutic options for lower urinary tract symptoms. Urology, 51(4A): 32, 1998. 

 

82.       Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, Te AE: Combination Therapy utilizing oral alpha blockers and intracavernosal injection in men with erectile dysfunction. Urology, 52(5): 739, 1998.

 

83.       Reis RB, Te AE, Cologna AJ, Suaid HJ, and Kaplan SA: Interstitial thermometry in men undergoing electrovaporization of the prostate. J Endourol, 13 (1):53 - 6, 1999.

 

84.       Kaplan SA, Staiman VB, Jacobs BZ, Reis B, Te AE: The ratio of transition zone volume to total prostate volume is higher in African - American men than in their Hispanic or Caucasian counterparts. British Journal Urology, February, 1999.

 

85.       Kaplan SA: Alternative instrumental treatments in BPH electrosurgery. Eur Urol, February, 1999.

 

86.        Weiner DM, Kaplan SA: Electrosurgery using the Vaportorde. Eur Urol 35(2): 166 – 72, 1999.

 

87.       Kaplan SA, Reis RB, Kohn IJ, Ikeguchi EF, Laor E, Te AE: Safety and efficacy of sildenafil in women with sexual dysfunction. Urology, March, 1999.

 

88.       Roehrborn C, Kaplan SA, Waldstreicher J: Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology, March, 1999.

 

89.       Kaplan SA: Uroselective alpha blockade for BPH: Clinical reality or marketing savvy? Urology, 54(5): 776 – 9, 1999.

 

90.       Hayek OR, Shabsigh A, Kaplan SA et al: Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a rapid reduction of blood flow. J Urol., 162 (4):1527-31, 1999.

 

91.       Kaplan N, Kaplan SA, Quinn S, Grossman EB: Doxazosin mesylate for the treatment of concomitant hypertension and benign prostatic hyperplasia: an open label study in patients with well – controlled hypertension. Am J. Med. October, 1999.

 

92.       Kaplan SA, Garvin D, Gilhooley P, Koppel M, Labasky R, Milstein R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F and Waldstreicher J for the PLESS Study Group. The impact of baseline symptom severity on future risk of BPH – related outcomes and long – term response to finasteride. Urology, July 2000.

 

93.       Shabsigh A, Hayek OR, Weiner D, Saidi J, Kaplan SA, Kiss A, Burchardt M, Buttyan R, Levin RM: Acute increase in blood flow to the rat bladder subsequent to partial bladder outlet obstruction. Neurourol Urodynam, 19:195-206, 2000.

 

94.       Kaplan SA, Stifelman M, Avillo C, Reis RB and Te AE: Detrusor contraction duration (DCD) may predict response to alpha blocker therapy for lower urinary tract symptoms. Eur Urol, 37 (3):314-317, 2000.

 

95.       Kaplan SA, Te AE, Young GHP, Andrade A, Cabelin MA and Ikeguchi EF: Prospective analysis of 373 consecutive women with stress urinary incontinence treated with a vaginal wall sling: the Columbia and Cornell University. J Urol, 164:1623 – 1627, 2000.

 

96.       Shabsigh A, Ghafar MA, De la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan R: Biomarker analysis demonstrates hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem, 81:437-444, 2001.

 

97.       Kaplan SA, Holtgrewe HL, Bruskewitz R, et al: Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology, 57(6): 1073 – 7, 2001.

 

98.       Kaplan SA: 5 – alpha reductase inhibitors: what role should they play? Urology, 58: 65 – 70, 2001.

 

99.        Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, Kaplan SA: The high prevalence of benign prostatic hyperplasia related urinary tract symptoms in Korean men is due to a high transition zone index. Eur. Urol., 42 (1): 7 - 11, 2002.

 

100.    Kruzer E and Kaplan SA: Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. European Urology, 42: 163 – 166, 2002.

 

101.    Ghafar MA, Anastasiadis AG, Olsson LE, Chichester P, Kaplan SA, Buttyan R, Levin RM : Hypoxia and an angiogenic response in the partially obstructed rat bladder. Laboratory Investigation, 82(7): 903 – 909, 2002. 

 

102.    Kaplan SA: Increased bladder apoptosis with alpha – 1 adrenoreceptor antagonists in benign prostatic hyperplasia. J Urol 169 (4), 1623, 2003.

 

103.    Kaplan SA: Quantitative evaluation of prostatectomy for benign prostatic hypertrophy under a national health insurance law: a multi-centre study.
   J Urol. 2003 Apr;169(4):1622.

 

104.    Kaplan SA: Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and 1D adrenergic receptor antagonists, on bladder activity in rats.

         J Urol 2003, 169 (4): 1621.

 

105.    Kaplan SA: Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. J Urol 2003, 169(4):1621.

 

106.     Kaplan SA: The value of power Doppler imaging to predict the histologic components of benign prostatic hyperplasia. J Urol 2003, 169 (4): 1620.

 

107.     Kaplan SA: Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. J Urol. 2003 Apr;169(4):1620.

 

108.    Kaplan SA: Association of polymorphisms within androgen receptor, 5 - alpha - reductase and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. J Urol. 2003, Apr;169(4):1619.

 

109.     Kaplan SA: Office-based transurethral microwave thermotherapy using TherMatrx TMx-2000. J Urol. 2003 Apr;169(4):1618-9.

 

110.      Kaplan SA, Ghafar MA, Lam JS, Fromer D, Te AE: Use of finasteride as a diagnostic tool in evaluating men with a serum PSA > 4 and previous negative prostate biopsy. Urology, 60 (3): 464 – 468, 2002. 

 

111.      Kaplan SA: Soy isoflavonoid equol modulates the growth of benign and malignant prostate epithelial cells in vitro. J Urol 170 (1): 339 – 340, 2003.

 

112.      Kaplan SA: Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. J Urol 170 (1): 340, 2003.

 

113.      Kaplan SA: Long term (7 – 8 year) experience with finasteride in men with benign prostatic hyperplasia. J Urol 170 (1): 341, 2003.

 

114.       Kaplan SA: Holmium laser enucleation for large (greater than 100 ml) prostate glands. J Urol 170 (1): 341 - 342, 2003.

 

115.      Kaplan SA: Sexual function in patients treated for benign prostatic hyperplasia reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. J Urol 170 (1): 342, 2003.

 

116.      Kaplan SA: Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs. transurethral resection or incision of the prostate: results of a randomized controlled study in patients with symptomatic benign prostatic hyperplasia. J Urol 170 (1):342 - 343,    2003.

 

117.      Kaplan SA: Serum human glandular kallikrein (hK2) and insulin – like growth factor 1 (IGF – 1) improve the discrimination between prostate cancer and benign prostate hyperplasia in combination with total and percent free PSA. J Urol 170 (1): 343, 2003.

 

118.      Kaplan SA: Effect of catheter size on urodynamic assessment of bladder outlet obstruction. J Urol 170 (1): 344, 2003.

 

119.      Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain R, Miller G, Crawford ED, Kaplan SA, Sihelnik SA, Brawer MK, Lepor H for the MTOPS Research Group. Controlled Clinical Trials, 24 (2): 224 – 43, 2003.

 

120.       McConnell JD………..Kaplan SA, et al : The long term effect of doxazosin, finasteride and combination therapy on clinical progression of lower urinary tract symptoms and benign prostatic hyperplasia in the Medical Therapy of Prostatic Symptoms (MTOPS) trial. NEJM, December, 2003. 

 

121.      Kaplan SA: Expression of Colony – stimulating factor 1 receptor during prostate development and prostate cancer progression. J Urol. 170(4): 1475 – 1476, 2003.

 

122.      Kaplan SA: Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption / ionization mass spectrometry. J Urol. 170 (4):1476, 2003.

 

123.      Kaplan SA: Differentiation of prostate cancer from benign prostate hypertrophy using dual – echo dynamic contrast MR imaging. J Urol. 170 (4): 1476, 2003.

 

124.      Kaplan SA: A randomized, double – blind crossover study of tamsulosin and controlled – release doxazosin in patients with benign prostatic hyperplasia. J Urol. 170 (4): 1477, 2003.

 

125.      Kaplan SA: Medical Therapy for Asymptomatic Men with BPH: Primum Non Nocere. Urology, 62(5):784 – 785, 2003.

 

126.      Kaplan SA: Heat versus drugs in the treatment of benign prostatic hyperplasia. J Urol. 170 (4): 1477 – 1478, 2003.

 

127.      Kaplan SA: Rotoresect for bloodless transurethral resection of the prostate: a 4 – year follow – up. J Urol. 170 (4): 1478, 2003.

 

128.      Kaplan SA: Benign prostate – specific antigen (BPSA) in serum is increased in benign prostate disease. J Urol. 170 (4): 1478 – 1479, 2003.

 

129.      Landis JR, Kaplan SA, Swift S: Impact of incontinence severity of antimuscarinic therapy in patients with overactive bladder. J Urol, 171(1):752 – 757, 2004.

 

130.      Weissman MM, Gross R, Fryer A, Heiman GA, Gameroff MJ, Hodge SE, Kaufman D, Kaplan SA: Interstitial cystitis and panic disorder: a potential genetic syndrome. Archives of General Psychiatry. 61: 273 – 279, 2004.  

 

131.      Kaplan SA, Volpe M, Te AE: A prospective one – year trial using saw palmetto versus finasteride in the treatment of category III prostatitis / chronic pelvic pain syndrome. J Urol, 171:345 – 349, 2004.

 

132.       Kaplan SA: Cholinergic innervation and function in the prostate gland. J Urol, 171(1): 538, 2004.

 

133.      Kaplan SA: Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage. J Urol, 171(1):538 – 539, 2004.

 

134.      Kaplan SA: Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – The Triumph Project. J Urol,171(1): 539 – 540, 2004.

 

135.      Kaplan SA: 5 – year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. J Urol, 171(1): 540, 2004.

 

136.      Kaplan SA: A 4 – year follow – up of a randomized prospective study comparing transurethral electrovaporization of the prostate with neodymium:Yag laser therapy for treating benign prostatic hyperplasia. J Urol, 171(1): 540, 2004.

 

137.      Kaplan SA: Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability of results obtained with the Targis system. J Urol, 171(1):    541 – 542, 2004.

 

138.      Kaplan SA: Minimal transurethral prostatectomy plus bladder neck incision versus standard transurethral prostatectomy in patients with benign prostatic hyperplasia: A randomized prospective study. J Urol, 171(1): 542, 2004.

 

139.      Kaplan SA: Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. J Urol, 171(1):542 – 543, 2004.

 

140.      Kaplan SA: Insulin – like growth factor I, insulin – like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. J Urol, 171(1):543, 2004.

 

141.      Kaplan SA: Apoptotic and proliferative index after alpha – 1 – adrenoreceptor antagonist and / or finasteride treatment in benign prostatic hyperplasia. J Urol, 171(1):543 – 544, 2004.

 

142.      Kaplan SA: Percent – free prostate specific antigen is elevated in men on hemodialysis or peritoneal dialysis treatment. J Urol, 171(1):544, 2004.

 

143.      Kaplan SA: Prostate cancer versus hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. J Urol, 171(1):538, 2004.

 

144.      Kaplan SA: BPH management: statistical significance may not translate into clinical relevance. J Urol, 171:1207 – 1208, 2004.

 

145.      Kaplan SA: Use and misuse of the concept of quality of life in evaluating surgical treatments for lower urinary tract symptoms. J Urol 171(4): 1751 – 1752, 2004.

 

146.      Kaplan SA: Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. J Urol 171(4): 1752, 2004.

 

147.      Kaplan SA: Long term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. J Urol 171(4):1752 - 1753,      2004.

 

148.      Kaplan SA: Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement. J Urol 171(4): 1753 – 1754, 2004.

 

149.      Kaplan SA: Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: aprospective study of 510 patients. J Urol 171(4):1754, 2004.

 

150.      Kaplan SA: Prostatic epithelial and luminal area in the transition zone acini: morphometric analysis in normal and hyperplastic human prostate. J Urol 171(4): 1754 – 1755, 2004.

 

151.      Kaplan SA: Holmium laser enucleation of the prostate: morbidity in a series of 206 patients. J Urol 171(4): 1755, 2004.

 

152.      Sandhu JS, Ng C, Egan C, Kaplan SA, Te AE: High-power potassium-titanyl- phosphate (KTP) photoselective laser vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) in men with large prostates. Urology, 64:1155 – 1159, 2004.

 

153.      Kaplan SA: Use of alpha adrenergic inhibitors in the treatment of benign prostatic hyperplasia. Urology, 63(3): 428 - 435.

 

154.      Walmsley K and Kaplan SA: Transurethral microwave thermotherapy (TUMT) for benign prostate hyperplasia (BPH) - Separating truth from marketing hype. J Urol, 172(4): 1249 – 1255, 2004.

 

155.      Kaplan SA: The long – term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. J Urol, 172(1): 413 – 414, 2004.

 

156.      Kaplan SA: Use of a – blockers and the risk of hip / femur fractures. J Urol, 172(1): 414, 2004.

 

157.      Kaplan SA: First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. J Urol, 172(1): 415, 2004.

 

158.      Kaplan SA: Phytomedicines for the prostate: J Urol, 172(1):415, 2004.

 

159.      Kaplan SA: The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. J Urol, 172(1):416, 2004.

 

160.      Kaplan SA: Variations of transition zone volume and transition zone index after transurethral needle ablation for symptomatic benign prostatic hyperplasia. J Urol, 172(1): 416 – 417, 2004.

 

161.      Kaplan SA: The effect of urethral instrumentation on uroflowmetry. J Urol,172(1):417 – 418, 2004.

 

162.      Kaplan SA: Nd:YAG laser ablation plus transurethral resection for large prostates in high – risk patients. J Urol, 172(1):418, 2004.

 

163.      Kaplan SA: Transurethral resection vs microwave thermotherapy of the prostate: a cost – consequence analysis. J Urol, 172(1):418 – 419, 2004.

 

164.      Kaplan SA: Expression of Protein C Inhibitor (PCI) in benign and malignant prostatic tissues. J Urol, 172(1): 419, 204.

 

165.      Kaplan SA: The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. J Urol, 172(1): 419 – 420, 2004.

 

166.      Kaplan SA: Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two – drug crossover study. J Urol, 172(4):1575, 2004.

 

167.      Kaplan SA: Metabolic profile in patients with benign prostate hyperplasia or prostate cancer and normal glucose tolerance. J Urol, 172(4): 1575 – 1576, 2004.

 

168.      Kaplan SA: Comparative efficacy of two a- adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement” J Urol, 172(4): 1576 – 1577, 2004. 

 

169.      Kaplan SA: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM – 7). J Urol, 172(4):1577, 2004.

 

170.      Kaplan SA: Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. J Urol, 172(4): 1577 – 1578,       2004.

 

171.      Kaplan SA: Expression of vascular endothelial growth factor receptor – 3 (VEGFR – 3) in human prostate. J Urol, 172(4): 1578, 2004.

 

172.      Kaplan SA: Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle. J Urol, 172(4): 1579, 2004.

 

173.      Kaplan SA: Androgen receptor gene polymorphism and increased risk of urologic measures of benign prostatic hyperplasia. J Urol, 172(4): 1579 – 1580, 2004.

 

174.      Kaplan SA: Intra – individual variation of serum prostate specific antigen levels in men with benign prostate biopsies. J Urol, 172(4): 1580, 2004. 

 

175.      Kaplan SA: Management of inguinal hernia with benign prostatic hyperplasia: simultaneous inguinal hernioplasty with transurethral resection of the prostate. J Urol, 173: 514, 2005. 

 

176.       Kaplan SA: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a – reductase inhibitor. J Urol, 173: 514 - 515, 2005.

 

177.      Kaplan SA: Efficacy and safety of dutasteride in the four – year treatment of men with benign prostatic hyperplasia. J Urol, 173: 515, 2005. 

 

178.      Kaplan SA: Modeling of the pH – and the temperature – dependent deviations of the free to total PSA (prostate specific antigen) ratios for clinical predictability of prostate cancer and benign prostate hyperplasia. J Urol, 173(4): 1266, 2005. 

 

179.       Kaplan SA: Updated meta- analysis of clinical trial of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. J Urol, J Urol 173: 516, 2005. 

 

180.      Kaplan SA: Apoptosis incidence and protein expression of p53, TGF – a receptor II, p27 kip 1 , and Smad4 in benign, premalignant and malignant human prostate. J Urol, 173(3): 912 – 913, 2005.

 

181.       Kaplan SA: Interleukin – 8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. J Urol, 173(3): 913, 2005. 

 

182.      Kaplan SA: Reduction of rat prostate weight by combined quercetin finasteride treatment is associated with cell cycle deregulation. J Urol, 173(3): 914, 2005. in press.

 

183.      Kaplan SA: Prostate – specific antigen in the assessment of organ donors. J Urol, 173(1): 161, 2005.

 

184.      Kaplan SA: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. J Urol, 173(1): 161, 2005. 

 

185.      Kaplan SA: The relation of lower urinary tract symptoms with life style factors and objective measures of benign prostatic enlargement and obstruction: An Italian survey. J. Urol, 173(6):2058, 2005.

 

186.      Kaplan SA: Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients – PERMAL study subset analysis. J Urol, 173(5):1667 - 1668, 2005.

 

187.      Kaplan SA: The role of lipido – sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol, 173(5):1667, 2005. 

 

188.      Kaplan SA: Lycopene: modes of action to promote prostate health. J Urol, 173(5): 1667, 2005. 

 

189.      Kaplan SA: Optimizing the medical management of benign prostatic hyperplasia. J Urol, 173(5):1666 – 1667, 2005. 

 

190.      Kaplan SA:   Andropause: endocrinology, erectile dysfunction, and prostate physiology. J Urol, 173(5):2058 – 2059, 2005. 

 

191.      Kaplan SA: Are indications for prostatectomy in octogenarians the same as for younger men? J Urol, 173(5):2059, 2005. 

 

192.      Kaplan SA: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase – 2, Bcl – 2 and cell proliferation in the glandular epithelium. J Urol, 173(4): 1266 – 1267, 2005.  

 

193.      Kaplan SA: The effect of combined androgen ablation on the expression of alpha 1A – adrenergic receptor in the human prostate. J Urol, 173(4): 1267, 2005. 

 

194.      Kaplan SA:   Three – year follow – up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. J Urol, 173(5): 1667 – 1668, 2005.

 

195.      Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol, 174: 2273 – 2276, 2005.

 

196.      Kaplan SA: In vitro assessment of the efficacy of thermal therapy in human benign prostatic hyperplasia. J Urol, 174(4): 1352, 2005.

 

197.      Kaplan SA: High – energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia: comparative study between 30 and 60 minute single treatments. J Urol, 174(4): 1352, 2005.

 

198.      Kaplan SA: Transurethral microwave thermotherapy vs. transurethral resectionfor treating benign prostatic hyperplasia: a systematic review. J Urol, 174(1):221 – 222, 2005.

 

199.      Kaplan SA: Intermittent catheterization time required after interstitial laser coagulation of the prostate. J Urol, 174(1): 222, 2005.

 

200.      Kaplan SA: The changing practice of transurethral prostatectomy: a comparison of cases performed in 1990 and 2000. J Urol, 174(1):221, 2005.

 

201.      Kaplan SA: Development and validation of a quality – of – life scale for Chinese patients with benign prostatic hyperplasia. J Urol, 174 (1): 224, 2005.

 

202.      Kaplan SA: Single – blind, randomized controlled study of the clinical and urodynamic effects of an a – blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. J Urol, 174(3): 1011, 2005.

 

203.      Kaplan SA: Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia. J Urol, 174(3): 1010 – 1011, 2005. 

 

204.      Kaplan SA: Induction and function of CYR61 (CCNI) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation. J Urol, 174(3):1012.

 

205.      Kaplan SA: BPH: Patient perceptions and financial reality regarding the aging American prostate. J Urol, 173(5):1852, 2005.

 

206.      Kaplan SA: Efficacy of extended – release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. J Urol, 174 (4): 1353, 2005.  

 

207.      Kaplan SA: Lower urinary tract symptoms: a hermeneutic phenomenological study into men’s lived experience. J Urol, 174(4): 1353 – 1354, 2005.

 

208.      Kaplan SA: Prospective randomized controlled trial comparing plasmakinetic vaporesection and conventional transurethral resection of the prostate. J Urol, 174:679, 2005.  

 

209.      Kaplan SA: The 12 – year outcome analysis of an endourethral Wallstent for treating benign prostatic hyperplasia. J Urol, 174(4): 1354 – 1355, 2005.

 

210.      Kaplan SA: Three – dimensional ultrasonography in evaluation of benign prostatic hyperplasia. J Urol, 174:1904, 2005.  

 

211.      Kaplan SA: Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. J Urol, 174: 1905, 2005.

 

212.      Kaplan SA: Patients with a large prostate show a higher prevalence of androgenic alopecia. J Urol, 174 (5): 1905, 2005.

 

213.      Kaplan SA: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase – 2, Bcl – 2, and cell proliferation in the glandular epithelium. J Urol, 174:2281, 2005.

 

214.      Kaplan SA: Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5a – reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. J Urol, 174:2282, 2005.

 

215.      Kaplan SA: A comparison of four different a1 – blockers in benign prostate hyperplasia patients with and without diabetes. J Urol, 174:2282 – 2283, 2005.

 

216.      Kaplan SA, Walmsley K and Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol, 174 (6): 2273 – 2276, 2005.

 

217.      Capodice JL, Bemis DL, Buttyan R, Kaplan SA, Katz AE: A literature review of complementary and alternative medicine for chronic prostatitis / chronic pelvic pain syndrome. Evidence based complementary and alternative medicine. http://ecam.oxfordjournals.org. October, 2005.

 

218.      Kaplan SA, DeRose AF, Kirby RS, O’Leary MP, McVary KT: Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health. BJU International. BJU Int. 97 (3):559-66, 2006.

 

219.      Giulliano F, Kaplan SA, Cabanis MJ: Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase 5 inhibitor tadalafil in middle-aged healthy male subjects. Urology, 67:1199 – 1204, 2006.

 

220.      Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z: Tolterodine extended release improves overactive bladder symptoms in continent men with overactive bladder and nocturia. Urology, 68:328 – 332, 2006.

 

221.      Kaplan SA: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. J Urol, 175(3): 1032 – 1033, 2006.

 

222.      Kaplan SA: Expression of cyclooxygenase – 1 and cyclooxygenase – 2 in the human prostate. J Urol, 175 (3): 1033, 2006.

 

223.      Kaplan SA: Prospective randomized controlled trial comparing plasmakinetic vaporesection and conventional resection of the prostate. J Urol 175 (3): 1033 – 1034, 2006.

 

224.      Kaplan SA: Feedback microwave thermotherapy with the ProstaLund compact device for obstructive benign prostatic hyperplasia: 12 month response rates and complications. J Urol, 175 (3): 1034 – 1035, 2006.

 

225.      Kaplan SA: Intraoperative floppy iris syndrome associated with tamsulosin. J Urol, 175: 2213, 2006

 

226.      Kaplan SA: Prostate size influences the outcome after presenting with acute urinary retention. J Urol, 175(1): 227 - 228, 2006.

 

227.      Kaplan SA: Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): A European multi – center evaluation. J Urol 175 (3): 1035, 2006.

 

228.      Kaplan SA: Acute urinary retention: what is the impact on patients’ quality of life? J Urol, 175 (1): 229, 2006. 

 

229.      Kaplan SA: Assessing prostate volume by magnetic resonance imaging. J Urol, in press. 175 (1): 228 – 229, 2006.

 

230.      Kaplan SA: Urgency of micturition and detrusor contractility in men with prostatic obstruction and overactive bladders. J Urol, 175(2): 633, 2006. 

 

231.      Kaplan SA: Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). J Urol, 175 (2): 633 – 634, 2006.

 

232.      Kaplan SA: Activation of Caspases – 3, - 6, and - 9 during finasteride treatment of benign prostatic hyperplasia. J Urol, 175(2): 634 – 635, 2006.

 

233.      Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM, for the MTOPS Research group. Relationship between prostate size and the effect of combination therapy with doxazosin and finasteride versus either drug alone on the clinical progression of benign prostatic hyperplasia. J Urol, 175:217-221, 2006.

 

234.      Abrams P, Kaplan SA, De Konig Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol, 175: 999 – 1004, 2006

 

235.      Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z: Efficacy and tolerability of tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence. BJU International, 97:1003 – 1006, 2006.

 

236.      Kaplan SA and Crawford ED: Choosing a safe strategy for androgen supplementation in men with low testosterone levels associated with the metabolic syndrome and/or type 2 diabetes. Diabetes Care, 29(3):749, 2006.

 

237.      Roehrborn CG and Kaplan SA: Optimising the management of patients with benign prostatic hyperplasia. BJU International 97(2): 1 – 45, 2006.

 

238.      Kaplan SA, Meehan AG, Shah A: The age-related decline in testosterone is significantly exacerbated in obese men with the metabolic syndrome? What are the implications of this for the relatively high incidence of erectile dysfunction observed in these men?" J Urol, 176: 1524 – 1527, 2006.

 

239.      Kaplan SA: Estradiol / androgen receptors during aging: microsomal distribution in human benign prostatic hypertrophy. J Urol, 175 (4): 1436, 2006.

 

240.      Kaplan SA: Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century. J Urol, 175(5): 1805, 2006.

 

241.      Kaplan SA: Prostate operations: long term effects on sexual and urinary function and quality of life. Comparison with an age – matched control population. J Urol, 175(5): 1805, 2006.

 

242.      Kaplan SA: Transurethral electrovaporization of the prostate: is it any better than standard transurethral prostatectomy? 5 – year follow – up. J Urol, 175 (5): 1804, 2006.

 

243.      Kaplan SA: Minimally invasive therapy for benign prostatic hyperplasia: practice patterns in Minnesota. J Urol, 175 (4): 1437 – 1438, 2006.

 

244.      Kaplan SA: Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. J Urol, 175 (6): 2211, 2006.

 

245.      Kaplan SA: Androgen regulation of JM – 27 is associated with the diseased prostate. J Urol, 175 (4): 1437, 2006.

 

246.      Gonzalez RR and Kaplan SA: Tadalafil for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Expert Opin Drug Metab and Toxic. 2(4): 609 – 617, 2006.

 

247.      Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Zhoughong: Tolterodine and tamsulosin for treatment of lower urinary tract symptoms and overactive bladder. A randomized controlled trial. JAMA, 296 (19): 2319 – 2328, 2006.

 

248.      Capodice JL, Jin Z, Bemis DL, Samadi D, Stone BA, Kaplan SA, Katz AE: A pilot study on acupuncture for lower urinary tract symptoms related to chronic prostatitis / chronic pelvic pain. Chinese Medicine. 2:1-6, 2007.

 

249.      Kaplan SA: Curvilinear transurethral ultrasound applicator for selective prostate thermal therapy. J Urol, 175 (6): 2213 – 2214, 2006.

 

250.      Kaplan SA: Comparison of tamsulosin and naftopidil and safety in treatment of benign prostatic hyperplasia: a randomized controlled trial. J Urol, 175 (6): 2212 – 2213, 2006.

 

251.      Kaplan SA: Long - term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5a – reductase inhibitor dutasteride: results of 4 – year studies. J Urol, 175 (6): 2211 – 2212, 2006.

 

252.      Dimitrakov JD, Kaplan SA, Kroenke K, Jackson JL, Freeman MR: Management of chronic prostatitis/ chronic pelvic pain syndrome: an evidence-based approach. Urology, 67: 881 – 888, 2006. 

 

253.      Gonzalez RR, Kaplan SA: First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment? World J Urol, 24(4):360 – 367, 2006.

 

254.      Kaplan SA and Neutel J: Vasodilatory factors in the treatment of older men with symptomatic benign prostatic hyperplasia. Urol, 67:225 – 231, 2006.

 

255.      Kaplan SA: The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6 – month analysis. J Urol, 176 (1): 273, 2006.

 

256.      Kaplan SA: Lifetime implications and cost – effectiveness of using finasteride to prevent prostate cancer. J Urol, 176 (1): 274, 2006.

 

257.      Kaplan SA: Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate – specific antigen in clinical routine. J Urol, 176 (3): 1061, 2006.

 

258.       Kaplan SA: Erectile dysfunction (ED) is prevalent, bothersome and under diagnosed in patients consulting urologists for benign prostatic syndrome (BPS). J Urol, 176 (1): 274 – 275, 2006.

 

259.      Kaplan SA: Resistance index in benign prostatic hyperplasia using power Doppler imaging and clinical outcomes after transurethral vaporization of the prostate. J Urol, 176 (2): 675, 2006.

 

260.      Kaplan SA: Measuring resistance index in patients with BPH and lower urinary tract symptoms. J Urol, 176 (2): 676, 2006.

 

261.      Kaplan SA: Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population – based cohort study in the Netherlands. J Urol, 176(3):1061, 2006.

 

262.      Kaplan SA: Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. J Urol, 176 (2): 676 – 677, 2006.

 

263.      Kaplan SA: Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double – blind placebo – controlled study. J Urol, 176 (2): 1062 – 1063, 2006. 

 

264.      Kaplan SA: The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. J Urol, 176 (2): 677, 2006.

 

265.      Kaplan SA: Long – term follow – up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. J Urol, 176 (2): 678, 2006.

 

266.      Kaplan SA and Naslund M: Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark study. J Clin Pract 60 (10):1157 – 1165, 2006.

 

267.      Kaplan SA: Voiding symptom evaluation: it is time to recalibrate. Eur Urol, June, 2006.

 

268.      Kaplan SA: Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of > 40 g. J Urol, 176(4:1):1511, 2006.  

 

269.      Kaplan SA: Long – term therapy with the dual 5a - reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. J Urol, 176 (5): 2123, 2006.

 

270.      Kaplan SA: A shifted paradigm for the further understanding, evaluation and treatment of lower urinary tract symptoms in men: focus on the bladder. J Urol, 176 (6): 2571, 2006.   

 

271.      Kaplan SA: Retinoic acid via RARa inhibits the expression of 24-hydroxylase in human prostate stromal cells. J Urol, 176 (6): 2572, 2006.

 

272.      Kaplan SA: Immunohistochemical expression of tumor antigens MAGE – AI, MAGE – A3/4 and NY – ESO – I in cancerous and benign prostatic tissue. J Urol, 176 (6): 2573 – 2574, 2006.

 

273.      Kaplan SA: Photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia. J Urol, 176(4:1): 1510, 2006.

 

274.      Kaplan SA: Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. J Urol, 176 (6): 2572 – 2573, 2006.

 

275.      Kaplan SA: The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992 – 2002). J Urol, 176 (5): 2123 – 2124, 2006. 

 

276.      Kaplan SA: Long – term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms – a placebo – controlled, double – blind, multicenter trial. J Urol, 176 (6): 2571 – 2572, 2006.

 

277.      Kaplan SA: Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. J Urol, 176 (5): 2122, 2006.

 

278.      Kaplan SA: Male pelvic health: A urologic call to arms. J Urol, 176 (6): 2351 – 2352, 2006.

 

279.      Staskin DR, Kaplan SA, Wein AJ: Antimuscarinic therapy in men with bladder outlet obstruction. Current Urology Reports, 6:437 – 439, 2006.

 

280.      Kaplan SA: Three months’ treatment with the a1 – blocker alfuzosin does not affect total or transition zone volume of the prostate. J Urol, 177 (1): 234, 2007.

 

281.      Kaplan SA: Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. J Urol in press. 177 (1): 235, 2007.

 

282.      Kaplan SA: Effects of a1 – adrenoreceptor antagonists in male sexual function. J Urol, 177(2): 623 – 624, 2007.

 

283.      Kaplan SA: Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. J Urol, 177 (2): 624 – 625, 2007.

 

284.      Kaplan SA: Metabolic factors associated with benign prostatic hyperplasia. J Urol, 177 (2): 623 – 624, 2007.

 

285.      Kaplan SA: Relationship between serum specific antigen and the pattern of inflammation in both benign and malignant prostatic disease in Middle Eastern men. J Urol, 177 (3): 1055 – 1056, 2007.

 

286.      Kaplan SA: Intraprostatic injection of botulinum toxin type – A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. J Urol, 177 (1): 235 – 236, 2007. 

 

287.      Kaplan SA: Identification of the patients with enlarged prostate: Diagnosis and treatment strategies. Osteopathic Medicine and Primary Care 1:11, 2007.

 

288.      Kaplan SA: New data: do recent findings dispel questions about treating overactive bladder in men. Eur Urol Supplements 6: 10 – 16, 2007.

 

289.      Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Zhoughong: Tolterodine and tamsulosin for treatment of lower urinary tract symptoms and overactive bladder. A randomized controlled trial. Response to Letter. JAMA: 297 (11): 1191 – 1193, 2007.

 

290.      Kaplan SA, Gonzalez RR, Te AE: Combination of an alpha -1 blocker, alfuzosin and a PDE – 5 inhibitor, sildenafil citrate is superior to monotyherapy in treating lower urinary tract symptoms and sexual dysfunction. Eur Urol, 51: 1717 –1723, 2007.

 

291.      Kaplan SA: Metabolic dysfunction and male pelvic health. Eur Urol, 52:316 –317, 2007.

 

292.      Rosenberg, MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, Ohl DA: A practical guide to the evaluation of male lower urinary tract symptoms in the primary care setting. IJCP, 61 (9): 1535 – 1546, 2007. 

 

293.      Kaplan SA: PDE – 5 inhibitors will have a beneficial effect in men with BPH. Eur

294.      Kaplan SABotulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol, 179 (1): 236, 2008.

 

295.      Kaplan SA: The effects of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms in men with BPH and prostatic enlargement: two – year results from the Combination of Avodart (dutasteride and tamsulosin (CombAT) study. J Urol, 179:620 – 621, 2008.

 

296.      Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD: Urinary retention and post void residual in men: separating truth from tradition. J Urol, in press.

 

297.      Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z: The effects of serum prostate-specific antigen level on the efficacy of tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder. Urology, in press.

 

298.      Cinar A, Hall SA, Link CL, Kaplan SA, Kopp ZS, Roehrborn CG, Rosen RC: Cluster analysis and lower urinary tract symptoms (LUTS) in men: findings from The Boston Area Community Health (BACH) Survey. BJU Int, in press

 

299.      Hall SA, Cinar A, Link CL, Kopp ZS, Roehrborn CG, Kaplan SA, Rosen RR: Do urologic symptoms cluster among women? Results from the Boston Area Community Health (BACH) Survey. BJU Int, in press.

 

300.      Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder: effects of prostate size. Eur     Urol, in press.

 

301.      Chapple CR, Wein AJ, Abrams PH, Dmochowski RR, Giuliano F, Kaplan SA, McVary KT, Roehrborn CG: Lower urinary tract symptoms revisised: a broader clinical perspective. Neurourolo Urodynam, in press.

 

302.      Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawashi S, Lee JY, Rotonda J, Kusek JW, Nyberg LM, for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group: Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. J Urol, in press.

 

303.      Rovner E, Kreder K, Sussman D, Kaplan SA, Carlsson M, Bavendam T, Guan Z: Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient – reported outcomes in men with lower urinary tract symptoms. J Urol, submitted.

 

304.      Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int, in press.

 

305.      Zoltan E and Kaplan SA: Ovreactive bladder and the effects of prostate volume. Current Bladder Dysfuction Reports, in press.

 

306.      Saini R and Kaplan SA: Lower urinary tract symptoms in men and incontinence in men. Up to date for Primary Care, in press.

 

307.      Kaplan SA: Holmium laser enucleation versus transurethral resection of the prostate: results from a 2 – center, prospective, randomized trisl in patients with obstructive benign prostatic hyperplasia. Editorial. J Urol, in press.

 

Invited Articles

 

1.            Kaplan SA, Blaivas JG: Bladder dysfunction in patients with multiple sclerosis. Contemporary Urology. 2:14 - 19, 1989.

 

2.            Kaplan SA, Brown WC, Blaivas JG: Management of bladder dysfunction in stroke patients. Contemporary Urology. 47 - 50, 1990.

 

3.            Kaplan SA, Blaivas JG: Management of BPH. Hospital Medicine. May 77 - 86, 1990.

 

4.            Chancellor MB, Kaplan SA, Blaivas JG: Detrusor-external sphincter dyssynergia. CIBA Symposium, Neurobiology of Incontinence, June, 1990.

 

5.            Kaplan SA, Koo HP: Prostatic Stents. In: Surgical Techniques in Urology. Volume 3: Issue 4 October 1990. 

 

6.            Kaplan SA and Lepor H: Prostate treatment without surgery. Executive Good Health Report, 1990.

 

7.            Stein BS, Stone NN and Kaplan SA: Update on Prostatic Disease: Benign Prostatic hyperplasia. Miles Publications. 1991.

 

8.            Kaplan SA, Ring KS, Sawczuk, IS: The use of a titanium prostatic stent in the management of acute urinary retention. Video Urology June 1991.

 

9.            Kaplan SA, Te A: Bladder dysfunction in diabetes. Problems in Urology. September 1992.

 

10.         Kaplan SA, Ring KS, Sawczuk IS: Titanium Stent in urinary retention. Video Urology Times. 5:1, 1992.

 

11.         Kaplan SA: Transrectal hyperthermia in the management of benign prostatic hyperplasia. Urologue, September 1992.

 

12.         Kaplan SA: Transrectal hyperthermia: Current Concepts. Contemporary Urology. March 1993.

 

13.         Kaplan SA: Prostatic urethral stents. Contemporary Urology. April 1993.

 

14.         Kaplan SA: Evaluation: the role of symptoms and urodynamic evaluation of benign prostatic hypertrophy. AUA/Merck Consultant Urologist, 1993.

 

15.         Kaplan SA, Shabsigh R, Soldo KA and Olsson CA: Prostatic and Periprostatic Interstitial Temperature Measurements Treated with Transrectal Thermal Therapy (Local Intracavitary Microwave Hyperthermia). Urology/Nephrology Digest, March, 1993

 

16.         Kaplan SA: Prostatic urethral stents. Semi Urol 12 (3):193-9, 1994.

 

17.         Te AE and Kaplan SA: Transurethral electrovaporization of the prostate (TVP): A novel modification of the standard TURP. Cont Urol 1995 May 7:74-83.

 

18.         Te AE and Kaplan SA: Electrovaporization of the prostate. Video Urology. October, 1995

 

19.         Kaplan SA: BPH: Options for Care. AUA Today. September, 1995.

 

20.         Te AE and Kaplan SA: Transurethral electrovaporization of the prostate: State of the art electrosurgery. Current Opinion in Urology. January, 1997.

 

21.         Santarosa RP, Te AE and Kaplan SA: Minimally invasive procedures for benign prostatic hyperplasia: electrovaporization, lasers, heat therapy and stents. In: Mediguide for Urology. Ed:    Carson CC.   1996; 9:1-6.

 

22.         Santarosa RP and Kaplan SA: Modified vaginal - wall sling for repair of vaginal prolapse. Current Surgical Techniques in Urology.   July, 1996.

 

23.         Santarosa RP and Kaplan SA: Urology Board review - BPH. Hospital Physician, November, 1996.

 

24.         Kaplan SA: BPH: Where are we in 1996? AUA Today. 1:3 1996.

 

25.         Hendricks JG and Kaplan SA: Erectile dysfunction and incontinence after radical retropubic prostatectomy. Contemporary Urology, 9:13 - 22, 1997.

 

26.         Kaplan SA: Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction. Editorial. Urology. 49:431, 1997.

 

27.         Kaplan SA: The postoperative morbidity of transurethral resection of the prostate and of four “minimally invasive” treatment alternatives. Editorial Comment. J Urol, 158:105, 1997.

 

28.         Kaplan SA: Voiding symptoms: Why do men under the age of 50 have them? Issues in Incontinence 4:1, 1997.

 

29.         Te AE and Kaplan SA: Electrovaporization of the Prostate. Endourology on CD - ROM. 1:1, 1997.

 

30.         Kaplan SA and Goluboff EG: Urology Board Review - Neurogenic Bladder (part 1). Hospital Physician, May (volume 5), 1997.

 

31.         Te AE and Kaplan SA: Electrovaporization of the prostate. Mayo Clinic Proceedings. 73:691 – 695, 1998.

 

32.         Kaplan SA: Pharmacologic Management of BPH. AUA Today. October, 1997.

 

33.         Kaplan SA and Klein LT: Practical Cases in Urology - Practical Management of BPH. November, 1997.

 

34.          Kaplan SA: Management of high – risk patients with benign prostatic hyperplasia: Long – term experiences with the Memotherm stent. Editorial comment. J Urol, 1998.

 

35.         Cooper KL, McKiernan JM, Kaplan SA: Alpha adrenoreceptor antagonists in the treatment of benign prostatic hyperplasia. DRUGS, January 57 (1): 9- 17, 1999.

 

36.         Kaplan SA: Transurethral resection of the prostate vs. transurethral electrovaporization of the prostate: A blinded, prospective comparative study with 1 – year follows – up. Response to letter. J. Urol, November, 1998.

 

37.         Kohn IJ and Kaplan SA: The potential clinical utility of iontophoretic drug delivery for urologic procedures. Contemporary Urology, November, 1998.

 

38.         Kaplan SA: The impact of the new paradigm in pharmacological management. New Concepts in the medical management of BPH. Johns Hopkins Press, 1998.

 

39.         Kohn IJ and Kaplan SA: Female sexual dysfunction: what is known and what remains to be determined. Contemporary Urology. October, 1999.

 

40.         Kaplan SA: Benign prostatic hyperplasia: transurethral treatment. Objectives for Urology Residency Education. Ed: Wein, AJ. 1999.

 

41.         Choi J, Ikeguchi EF, Te AE, Kaplan SA: Review of laser prostatectomy. Urology Review, July, 1999.

 

42.          Kohn IJ and Kaplan SA: Female sexual dysfunction: what is known and what remains to be determined. Contemporary OB/GYN. Vol 45:2, 2000.  

 

43.         Cabelin MA, Te AE, Kaplan SA: Benign prostatic hyperplasia: Challenges for the new millennium. Current Opinion in Urology. 10:301-306, 2000.

 

44.         Cabelin MA, Te AE, Kaplan SA: Transurethral electrovaporization of the prostate. Current Opinion in Urology. 10:306 – 310, 2000.

 

45.          Kaplan SA: What makes us different? Curr Urol Rep 1(1): 1 – 2, 2000.

 

46.         Kaplan SA: Benign prostatic hyperplasia: many new options, same old approach. Curr Urol Rep 1(2):83, 2000.

 

47.         Cabelin MA, Te AE, Kaplan SA: Transurethral electrovaporization of the prostate. Current Urology Reports. 1(2): 116 – 23, 2000.

 

48.         Volpe MA, Fromer D, Kaplan SA: Holmium and interstitial lasers for the treatment of BPH: a laser revival. Current Opinion in Urology. 11(1): 43 – 8, 2001.

 

49.         Cabelin M and Kaplan SA: Benign prostate hyperplasia: Update on new technology. Contemporary Urology. May, 2001.

 

50.          Kaplan SA: Human comfort: more than modern technology. Curr Urol Rep 2(6): 413 – 414, 2001.

 

51.          Blute ML, Jacobsen SJ, Kaplan SA, Lowe FC, O’Leary MP, Steers WD, Roehrborn, CG: Introduction to new therapies for BPH. Urology, 58(6) 1 – 4, 2001.

 

52.         Fromer D and Kaplan SA: Benign prostatic hyperplasia. In: Conn’s textbook of Medicine. 2002.

 

53.         Kaplan SA: Female Sexual dysfunction. Patient Care, February, 2002. 

 

54.         Lam J, Volpe, Kaplan SA: Stents in the management of men with BPH. Current Urology Reports, 2 (4): 277 – 84, 2001.

 

55.         Littlejohn JO, Ghafar MA, Kang YM, Kaplan SA: TURP: The new old standard. Current Opinion in Urology. 2002, 12:19 – 23.

 

56.         Lam JS, Volpe MA, Kaplan SA: Transurethral resection and incision of the prostate. Atlas of the Urologic Clinics of North America 10: 27 – 43, 2002.

 

57.         Cabelin MA, Ghafar MA, Te AE, Kaplan SA : Transurethral vaporization of the prostate. Atlas of the Urologic Clinics of North America 10: 45 – 49, 2002.

 

58.         Kaplan SA: Alpha blocker therapy for BPH. AUA News, November 2002.

 

59.          Kaplan SA: Reproducibility and clinical and concurrent validity of the MSF- 4: a four- item male sexual function questionnaire for patients with benign prostatic hyperplasia. J Urol. 2002 Oct;168(4 Pt 1):1661-2.

 

60.         Kaplan SA: Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long term data J Urol. 2002 Oct;168(4 Pt 1):1661.

 

61.         Kaplan SA: Practice trends in the management of prostate disease by family practice physicians and general internists: an Internet-based study.J Urol. 2002 Oct;168(4 Pt 1):1660-1.

 

62.          Kaplan SA: Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. J Urol. 2002 Oct;168(4 Pt 1):1660.

 

63.          Kaplan SA: Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. J Urol. 2002 Oct;168(4 Pt 1):1659-60.

 

64.         Kaplan SA: Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J Urol. Oct;168:1659, 2002.

 

65.         Kaplan SA: Characterization of cultured human prostatic epithelial cells bycluster designation antigen expression. J Urol. 2002 Oct;168(4 Pt 1):1658-9.

 

66.         Kaplan SA: Effects of mepartricin on estradiol and testosterone serumlevels and on prostatic estrogen, androgen and adrenergic receptor concentration in adult rats. J Urol. 168(4 Pt 1):1658, 2002.

 

67.         Kaplan SA: Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol. 2002 Oct: 168(4 Pt 1):1657-8.

 

68.         Kaplan SA: Comparison of long-term results of transurethral incision of theprostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy. J Urol. 2002 Oct;168(4 Pt 1):1657.

 

69.         Littlejohn JO and Kaplan SA: An unexpected association between urinary incontinence, depression, and sexual dysfunction. Drugs Today, February, 2003.

 

70.         Ogiste JS, Cooper KL, Kaplan SA: Are stents still a useful therapy for BPH? Current Opinion in Urology, 13 (1): 51 – 57, 2003.

 

71.         Kaplan SA: BPH medical therapy in 2003. AUA News, April, 2003.

 

72.         Kohn IJ, Te AE, Kaplan SA : Electrical stimulation and neuromodulation in the treatment of lower urinary tract dysfunction. AUA Updates, Volume XXII, #9, 2003.

 

73.          Kaplan SA: Men’s health: new insights into BPH and sexual function. Medical Education Resources, September, 2003.

 

74.          Kaplan SA: Molecular marker for interstitial cystitis. AUA News, September, 2003.

 

75.         Cooper KL, Anastasiadis AG and Kaplan SA: Minimally invasive therapies for BPH: variations of the same theme? Contemporary Urology, April, 2004.

 

76.          Lam JS, Cooper KL, Kaplan SA: Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia. Medical Clinics of North America, 88(2):281 – 309, 2004.

 

77.       Kaplan SA: BPH : new paradigms, new approaches. Urology Times 31(11), 2003.

 

78.        Kaplan SA: Medical management of BPH: New paradigms, new approaches. Urology Times, November, 2003. 

 

79.       Kaplan SA: Prostate histopathology. J Urol, 171:1385, 2004. 

 

80.        Gjertsen CK, Walmsley K, Kaplan SA: BPH: An update on diagnosis and therapeutic options. Cleveland Clinic Review, 71(11), 2004.

 

81.         Walmsley K, Gjersten CK, Kaplan SA: Medical management of BPH – an update. AUA Update, November, 2004.

 

82.          Kaplan SA: BPH management in 2004. AUA News, November 2004.

 

83.          Kaplan SA: Concomitant use of an artificial urinary sphincter device and a Urolume for men with sphincteric incontinence. AUA News, December, 2004.

 

84.          Kaplan SA: An update of the AUA Guidelines. Medical Reviews, 7(6): 324-354, 2004.

 

85.          Kaplan SA: The relationship between sexual function and voiding function: implications for diagnosis and treatment. AUA News, March, 2005.

 

86.          Jaffe W and Kaplan SA: The Epidemiology and Pathophysiology of Benign Prostatic Hyperplasia. Atlas of the Prostate, 3rd edition. July, 2005.

 

87.          Kaplan SA: Factors predicting failure with medical therapy for BPH. Medical Reviews. 7(7): 534 – 539, 2005. 

 

88.          Kaplan SA: Alpha blocker therapy: Current Update. Medical Reviews, 7(8):534 – 542, 2005.

 

89.         Rusnack SL, Kaplan SA: The use of botulinum toxin in men with benign prostatic hyperplasia. Medical Reviews, November, 2005.

 

90.          Kaplan SA: Association between LUTS and sexual function. Scientific World Journal. December, 2005.

 

91.          Kaplan SA: The role of muscarinic receptor antagonists in the treatment of men with lower urinary tract symptoms secondary to BPH. American Journal of Urology, 3:11:8, November 2005. 

 

92.         Kaplan SA and Roehrborn CG: Optimizing the management pf patients with benign prostatic hyperplasia. BJU supplement, April, 2006i.

 

93.          Kaplan SA: Benign prostatic hyperplasia guidelines: how can they be useful to primary care. Cornell Urology Reports on Men’s Health, Volume 1:1, 2006.

 

94.          Kaplan SA: Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices. Medical Reviews, 8 (1):2006. 

 

95.         Kaplan SA and Gonzalez RR: PDE – 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH). AUA News 11(3): 25 – 27, 2006.

 

96.          Kaplan SA: Editorial comment RE: Hartung R, et al: Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol, 175: 624 – 628, 2006.

 

97.          Jaffe WI and Kaplan SA: Benign prostatic hyperplasia: markers of progression. AUA Update, in press.

 

98.          Kaplan SA: Evolving insights into male LUTS. AUA News, November 2006

 

99.          Kaplan SA: BPH 2006: are we treating a new disease? AUA News, October, 2006

 

100.     Kaplan SA and Gonzalez RR: PDE5 inhibitors for the treatment of male lower urinary tract symptoms. Reviews in Urology, 8 (suppl 3): S3 – S8, 2006.

 

101.     Kaplan SA: Different indications and settings for photoselective vaporization prostatectomy (PVP). Med Reviews, 8(3): S3 – S7, 2006.

 

102.     Kaplan SA: An update on the American Urological Association guidelines for the treatment of BPH. Med Reviews, in press.

 

103.     Kaplan SA: Men’s theories about benign prostatic hyperplasia and prostate cancer following a benign prostatic hyperplasia decision aid. J Urol, 177 (3): 1056 – 1057. 2007.

 

104.     Kaplan SA: Saw palmetto – induced pancreatitis. J Urol, 177 (2): 625 – 626, 2007. 

 

105.     Kaplan SA: Immunohistochemical detection of cysteine – rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. J Urol, 177 (3): 1055, 2007.

 

106.     Kaplan SA: Pre – clinical evidence for the use of phosphodiesterase – 5 nhibitors for treating benign prostatic hyperplasia. J Urol, 177 (4): 1430 – 1431, 2007.

 

107.     Kaplan SA: Hyperinsulinemia and dyslipidemia in non – diabetic benign prostatic hyperplasia. J Urol, 177 (4): 1431 – 1432, 2007.

 

108.     Kaplan SA: Turbulent urinary flow in the urethra could be a causal factor for benign prostatic hyperplasia. J Urol, 177 (4): 1432 – 1433, 2007.

 

109.     Kaplan SA: Impact of surgical treatment on nocturia in men with benign prostatic obstruction. J Urol, 177 (5): 1823, 2007

 

110.     Kaplan SA: Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate – specific antigen. J Urol, 177 (5):1824, 2007.

 

111.     Kaplan SA: Comparative study of zinc levels in benign and malignant lesions of the prostate. J Urol, 177 (5): 1824 – 1825, 2007.

 

112.     Kaplan SA: Survey on the Italian outpatient urologists regarding the management of benign prostatic hyperplasia. J Urol, 177 (6): 2247 – 2248, 2007.

 

113.     Kaplan SA: The thermo – expandable metallic stent for managing benign prostatic hyperplasia: a systematic review. J Urol, 177 (6): 2248, 2007.

 

114.     Kaplan SA: Analysis of prognostic factors regarding the outcome after a transurethral resection for symptomatic benign prostatic enlargement. J Urol, 177 (6): 2249, 2007.

 

115.     Kaplan SA: Inhibition of testosterone induced hyperplasia of the prostate of Sprague – Dawley rats by pumpkin seed oil. J Urol, 177 (4): 1582 – 1583, 2007.

 

116.     Kaplan SA: Transurethral microwave thermotherapy effectiveness in small prostates. J Urol, 178:222 – 223, 2007. 

 

117.     Kaplan SA: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. J Urol, 178 (2): 587 – 588, 2007. 

 

118.     Kaplan SA: Naftopidil monotherapy vs. naftopidil and an anticholinergic agent

            combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled trial. J Urol, 178 (2): 588 – 589, 2007. 

 

119.     Kaplan SA:  Simple case definition of clinical benign prostatic hyperplasia, based on international prostate symptom score, predicts general practitioner consultation rates. J Urol, 178(3): 1005 – 1006, 2007.

 

120.     Kaplan SA: Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. J Urol, 178: 223 – 224, 2007.

 

121.     Kaplan SA: Racial differences in pathogenetic mechanisms, prevalence, and progression of benign prostatic hyperplasia. J Urol, 178 (3): 1007, 2007.

 

122.     Kaplan SA: Linguistic adaptation and validation of the Spanish version of the benign hyperplasia – patient impact measure (BPH – PIM). J Urol, 178 (3): 1006, 2007.

 

123.     Kaplan SA: Are lower urinary tract symptoms associated with erectile dysfunction in aging males of Taiwan? J Urol, 178 (3): 1007 – 1008, 2007.

 

124.     Kaplan SA: Long term results of medical treatment in benign prostatic hyperplasia. J Urol, 178(2):586 – 587, 2007. 

 

125.     Lee R, Saini R, Kaplan SA, Te AE: Review of transurethral microwave thermotherapy. AUA Update, August, 2007.

 

126.     Kaplan SA: Characteristics of patients presenting with LUTS / BPH in six European countries. J Urol, 178 (4): 1387 - 1388, 2007. 

 

127.     Kaplan SA: Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a case – control study in Western Australia. J Urol, 178 (4): 1388 - 1389.

 

128.     Kaplan SA: a1 – adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. J Urol, 178 (6): 2505 – 2506, 2007.

 

129.     Kaplan SA: Diet and benign prostatic hyperplasia: implications for prevention. J Urol, 178 (6): 2506, 2007. 

 

130.     Kaplan SA: Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. J Urol, 178 (4): 1389 - 1390.

 

131.     Kaplan SA: PSA velocity in conservatively managed BPH: can it predict the need for BPH – related invasive therapy? J Urol, 178 (5): 2057 – 2058, 2007.

 

132.    Kaplan SA: Bipolar transurethral resection of prostate in saline: preliminary report on clinical efficacy and safety at 1 year. J Urol, 178 (6): 2506 – 2507, 2007.

 

133. Kaplan SA: Pygeum africanum extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts. J Urol, 178 (5): 2058 – 2059, 2007.

 

134. Kaplan SA: Evidence of a novel biomarker, as1 – Casein, a milk protein, in benign prostate hyperplasia. J Urol, 178 (5): 2059, 2007.

 

135.   Kaplan SA: Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case – controlled study from Italy. J Urol, 178 (6): 2507 – 2508, 2007.

 

136.     Kaplan SA: CYR61, a cellular proliferation marker in dogs with prostate disease. J Urol, 178:351. 2007.

 

137.     Kaplan SA: Male Lower Urinary Tract Symptoms: New Approaches. Medscape, September, 2007.

 

138.     Kaplan SA: Male pelvic health: Review of AUA course. AUA News, December, 2007.

 

139.     Kaplan SA: The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. J Urol, 179 (1): 236 – 237, 2008.

 

140.     Kaplan SA: Effect of tolterodine in preventing urge incontinence immediately after prostatectomy. J Urol, 179 (1): 237 – 238, 2008.

 

141.     Kaplan SA: Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. J Urol, 179 (1): 237 – 238, 2008.

 

142.     Kaplan SA: Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. J Urol, 179 (1): 238 – 239, 2008.

 

143.     Kaplan SA: Bipolar transurethral resection of the prostate – technical modifications and early clinical experience. J Urol, 179 (2): 624, 2008.

 

144.     Kaplan SA: Is the short - term outcome of transurethral resection of the prostate affected by preoperative degree of bladder outlet obstruction, status of detrusor contractility or detrusor overactivity? J Urol, 179 (2): 625, 2008.

 

145.     Kaplan SA: The correlation between metabolic syndrome and prostatic growth with benign prostatic hyperplasia. J Urol, in press.

 

146.     Kaplan SA: Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? J Urol, in press.

 

147.     Kaplan SA: Changes of sexual function in patients before and after Ho:YAG l l laser enucleation of the prostate. J Urol, 179(2): 625 – 626, 2008.

 

148.     Kaplan SA: Atherosclerosis as a risk factor for benign prostatic hyperplasia. J Urol, in press.

 

149.     Kaplan SA : Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. J Urol, in press.

 

150.     Kaplan SA: Resting heart rate in cardiovascular disease. J Urol, in press.

 

151.     Kaplan SA: Acute urinary retention: medical management and the identification of risk factors for prevention. J Urol, in press.

 

152.     Kaplan SA: A large retrospective analysis of acute urinary retention and prostate – related surgery in BPH patients treated with 5 – alpha reductase inhibitors: dutasteride versus finasteride. J Urol, in press.

 

153.     Kaplan SA: Durability of 30 – minute high energy transurethral microwave therapy for treatment of benign prostatic hyperplasia: a study of 213 patients with or without urinary retention. J Urol, in press.

 

154.     Kaplan SA: Efficacy and tolerability of the dual 5a - reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African – American men. J Urol, in press.

 

155.     Kaplan SA: Safety and effectiveness of photoselective vaporization of the prostate in patients on ongoing oral anticoagulation. J Urol, in press.

 

156.     Kaplan SA: Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample. J Urol, in press.

 

157.     Kaplan SA: Obesity and benign prostatic enlargement: a large observational study in China. J Urol, in press.

 

158.     Kaplan SA: Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. J Urol, in press.

 

159.     Kaplan SA: Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. J Urol, in press.

 

160.     Kaplan SA: Silodosin, a new a 1A - adrenoreceptor – selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo – controlled, double – blind study in Japanese men. J Urol, in press.

 

161.     Kaplan SA: The changing world of medical therapy for symptomatic benign prostate hyperplasia. Cornell Urology Men’s Health for Primary Care Physicians, in press.

 

Books, book chapters and reviews

 

Books

 

·         Benign Prostatic Hyperplasia: Laser and Heat Therapy. Eds: Paul Miller, Ian Eardley, Steven Kaplan. Martin Dunitz LTD, 2001

·         Minimally Invasive Treatments in Urology Eds: Steven Kaplan, Alan Partin, Anthony Atala, 2005

·         Atlas of the Urologic Clinics of North America. Eds: Mark A. Cabelin and Steven Kaplan, 2003

 

Book Chapters

 

1.                  Hensle TW, Kaplan SA: Surgical on the lower ureter: an overview. In: Genitourinary Surgery. Ed: Droller. 1991.

 

2.                  Hensle TW, Kaplan SA: Lower ureteral reconstruction and reimplantation. In: Genitourinary Surgery. Ed: Droller. 1991.          

 

3.                  Kaplan SA, Benson MC: The urologic manifestations of AIDS. AIDS and Rehabilitative Medicine. Ed. Mukand JM. McGraw-Hill. 1992.

 

4.                  Kaplan SA: Bladder dysfunction. Lebovitz H. Ed., Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association. page: 288, 1992.

 

5.                  Kaplan SA: Prostatic Endoprostheses: In: Alternative Treatment of BPH. Ed: Vaughan ED and Romas N: May, 1993.

 

6.                  Kaplan SA: The neurogenic bladder. Current Therapy in Urology. Ed.: Steer WD. Gower Press. 1993

 

7.                  Kaplan SA: Non-medical alternative therapy in BPH. In: Nephrology and Urology in the Aged Patient. Oreopolous DG, Michelis, MF and Herschorn, S (eds.). Ch. 58, pp:523-44, 1993.

 

8.                  Kaplan SA, Blaivas JG, Bruer A: Urogenital physiology. In: Rehabilitation Medicine. Ed: Downey. January, 1994.

 

9.                  Kaplan SA, Dowd, JB: Non medical, alternative therapy for BPH. In: Handbook for BPH, Ed: Chisolm, G. Raven-Gower press, New York. May, 1994.

 

10.              Kaplan SA, Blaivas JG: The evaluation and management of the neurogenic bladder. Pang D (ed.) Disorders of the Pediatric Spine. Raven Press, 1994.

 

11.              Kennedy WC, Kaplan SA, Benson MC: Renal and Urologic Aspects of HIV Infection. In: HIV and the Kidney. Eds: Kimmel PL and Berns. Churchill Livingstone, 1994.

 

12.              Te AE and Kaplan SA: Pharmaceutical treatment of BPH and its effect on indications for prostate surgery. Surgical Technology International, 3rd Edition. Szabo Z, Kerstein MD, Lewis JE, Eds. Universal Medical Press, Inc. San Francisco, 1994.

 

13.              Kaplan SA and Bowers DL: Themotherapy of the prostate: transrectal hyperthermia. Smith’s Textbook of Endourolgy. Eds: Smith A and Badlani GH. 1996.

 

14.              Kaplan SA: Prostatic endoprosthetics. In: Textbook of Endourology. Eds: Sosa E, Albala DM, Jenkins AD, Perlmutter AP. WB Saunders, 1996.

 

15.              Te AE and Kaplan SA: Urodynamics in BPH. In: Textbook of Benign Prostatic Hyperplasia. Eds: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Isis Medical Media Ltd., Oxford, England. 1996. 

 

16.              Te AE and Kaplan SA: Prostatic endoprosthetics. In: Textbook of Benign Prostatic Hyperplasia. Eds: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Isis Medical Media Ltd,   Oxford, England. 1996.

 

17.              Gibbons RP, Altwein JE, Bruskewitz RC, Choquenet C, Costello AJ, Flam TA, Fourcade RO, Koshiba K, McNicholas TA, Stein BS, Kaplan SA: Surgical and Laser Treatment. 3rd International Consultation on Benign Prostatic Hyperplasia. ED: Cockett ATK, Khoury S, Aso Chatelain C, Denis L, Griffiths K, Murphy G. SCI Ltd., 1996.

 

18.              Kaplan SA and Jacobs BZ: Urinary incontinence in patients with Parkinson’s Disease. In: Parkinson’s Disease. Kuttscher, A. 1996

 

19.              Santarosa RP and Kaplan SA: Transurethral resection of the prostate. In: Operative Urology.   Eds: Krane RJ, Fitzpatrick J, Siroky MB. Churchill Livingstone, 1996.

 

20.              Te AE and Kaplan SA: Electrovaporization principles. In: Prostate Surgery. Ed: Narayan. 1997.

 

21.              Roehrborn CG, Andersen jT, Correa R, Di Silverio F, Kaplan SA, Kurth KH, Rubben H, Torp - Pedersen ST, Watanabe H, Zerbib M: Initial diagnostic evaluation of men with lower urinary tract symptoms. 3rd International Consultation on Benign Prostatic Hyperplasia. ED: Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G. SCI Ltd., 1996.

 

22.              Santarosa RP, Te AE, Kaplan SA: Transurethral resection, incision and ablation of the prostate. Glenn’s Urologic Surgery, 5th edition. Ed. Graham SD. 1997.

 

23.              Staiman VR and Kaplan SA: Bladder dysfunction. Lebovitz H. Ed., Therapy for Diabetes Mellitus and Related Disorders. American Diabetes Association. page: 288, 1997.

 

24.              Te AE, Santarosa RP, Kaplan SA: Electrovaporization of the prostate: advanced application of electrosurgical principles to the treatment of benign prostatic hyperplasia, In: Recent Advances in Urology. ED: Kirby RS, O’Leary MP, Churchill Livingstone, 1998.

 

25.              Te AE and Kaplan SA: Complications of Minimally Invasive Surgery for BPH. In: Complications in Urologic Surgery. Eds: Taneja, Smith & Ehrlich. 2000.

 

26.              Kohn I and Kaplan SA: Medical therapy of BPH. Atlas of Clinical Urology. Eds. Vaughan ED and Perlmutter A. 2000.

 

27.              Kohn IJ and Kaplan SA: Lower urinary tract obstruction. In: Surgery. EDS: Carson CC, 2001.

 

28.              Kohn IJ, Te AE and Kaplan SA: Urodynamics of prostatitis. In: Textbook of prostatitis. EDS: Nickel JC. 2000.

 

29.              Te AE, Ikeguchi EF, Choi J, Kaplan SA: Urodynamics and benign prostatic hyperplasia. In: Textbook of benign prostatic hyperplasia. Eds: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Isis Medical Media Ltd., Oxford, England. 2000.

 

30.              Cabelin M, Te AE and Kaplan SA: Urogenital physiology. In: Rehabilitation Medicine. Ed: Downey and Leiberman. 2000.

 

31.              Knowles D, Volpe M and Kaplan SA: Sexual dysfunction. In: Pelvic Disorders. Ed:Bourcier AP, McGuire EJ and Abrams P. Harcourt Health Sciences (WB Saunders), Philadelphia, PA. 2001.

 

32.               Littlejohn JO, Kang YM, Kaplan SA: Transurethral vaporization of the prostate. In: Management of Benign Prostatic Hypertrophy. ED: McVary KT. Humana Press. 2004

 

33.              Cooper KL, Kaplan SA: Overactive Bladder and Incontinence. In: Men’s Health volume 2. Eds: Kirby RS, Carson C, Kirby MG, Farah RN. Martin Dunitz, London, 2003 (In Press, Fall 2003)

 

34.              Walmsley K, Gjersten CK, Kaplan SA: Medical management of BPH – an update. Campbell’s Urology. Volume 2, Number 2, 2004. 

 

ABSTRACTS (25 of 135)

 

1)                Kaplan SA, Chancellor MB, Blaivas JG: A urodynamic evluation of bladder and sphincter behavior in patients with spinal cord lesions. J Urol 143:371A, 1990.

 

2)                Kaplan SA, Buttyan R, Olsson CA, Koo HP: SGP-2 Expression in diabetic rat bladders: evidence of acute injury. 14th International Diabetes Federation Congress. June 1991.

 

3)                Kaplan SA: "Prostatic stents in the management of geriatric men with prostatism.   Urodynamics     Society, May 1992.

 

4)                Te AE, Buttyan R, Koo HP, Olsson CA, Kaplan SA: Nerve growth factors in diabetic cystopathy. International Continence Society. September 1992.

 

5)                Kaplan SA, Blaivas JG, Te AE: Urodynamic findings in patients with diabetic and voiding symptoms: Surprising results. International Continence Society.   September 1992. 

 

6)                Kaplan SA, Olsson CA: Urodynamic evidence of vesical neck obstruction in men with chronic prostatitis and the therapeutic role of TUIP. J. Urol., 149:406A, 1993.

 

7)                Kaplan SA: Alpha blockade: monotherapy for hypertension and BPH. 3rd International Conference on BPH. Monte Carlo, June 1995. 

 

8)                Kaplan SA, Santarosa RP and Te AE: The incidence of hypertension in men with benign prostatic hyperplasia. XIIth European Urology Association, Paris, 1996.

 

9)                Kaplan SA: The ratio of transition zone to total prostate volume is higher in African - American men than in their Caucasian or hispanic counterparts. XXIIth European Urology Association, Paris, 1996.

 

10)            Kaplan SA, Laor E and Te AE: Transurethral rsection of the prostate (TURP) versus electrovaporization of the prostate (VAP): a prospective, blinded comparative study of the treatment of benign prostatic hyperplasia (BPH). XXIIth European Urology Association, Paris, 1996.

 

11)            Kaplan SA, Short K, Geller J et al: Baseline symptoms determine long-term symptomatic response to finasteride: Results of a four-year, placebo-controlled trial. European Urology Association, February, 1998, Barcelona, Spain.

 

12)            Kaplan SA for the NIH MTOPS Study Group: Medical therapy of prostate symptoms (MTOPS): baseline urodynamic data and correlation with prostate volume and prostate specific antigen (PSA). J Urol (159): 330, 1998.

 

13)            Kaplan SA, Blute M, Bruskewitz RC, Larson TR, Utz W, Ugarte R, Mayer R: Long term efficacy and durability in 345 patients treated with transurethral microwave thermotherapy for benign prostatic hyperplasia: Five year results. J Urol, 167 (4):1153, 2002.

 

14)            Kaplan SA and Te AE: Electrovaporization of the prostate utilizing the roller ball and / or vaporizing loop for symptomatic benign prostatic hyperplasia (BPH): The 7 – year Columbia experience in 650 consecutive men. J Urol, 167 (4):169, 1437, 2002.

 

15)            Kaplan SA and Te AE: Pressure / Flow evaluation of ethnically diverse men treated by minimally invasive surgical therapies for BPH: The New York Presbyterian Hospital experience. J Urol, 167 (4):1454, 2002.

 

16)            Kaplan SA, Roehrborn CG, McConnell JD: Baseline symptoms, uroflow, and post void residual urine as predictors of BPH clinical progression in the medically treated arms of MTOPS. J Urol, 169 (4): 1289, 2003.

 

17)      Kaplan SA, Olsson CA, Gross R, Kaufman D, Gameroff MJ, Weissman MM: Chromosome 13 syndrome: A pleiotropic genetic linkage between panic disorder and interstitial cystitis. J Urol 171 (4): 522, 2004.

 

18)      Kaplan SA, Walmsley K, Te AE: Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers. J Urol 171 (4): 917, 2004.

 

 19)     Kaplan SA, Roehrborn C, Lee M, The Medical Therapy of Prostatic Symptoms (MTOPS) Research Group: The superior beneficial effect of combination therapy with doxazosin and finasteride versus either drug alone on clinical progression of benign prostatic hyperplasia in the MTOPS trial was not dependent on patients having prostatic enlargement at baseline. Eur Urol, 4(3): 841, 2005.

 

20)      Kaplan SA, Roehrborn CG, Lee MW, and the MTOPS Research Group: The superior beneficial effect of combination therapy with doxazosin and finasteride versus either drug alone on clinical progression of benign prostatic hyperplasia is not dependent on patients having prostate enlargement at baseline: data from the medical therapy of prostatic symptoms (MTOPS) trial. J Urol 173 (4): 443, 2005.

 

21)      Kaplan SA, Gonzalez R, Ogiste J, Te AE: Combination of an a1 – blocker, alfuzosin and a PDE5        inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms          and sexual dysfunction. Eur Urol 592:197, 2006.

 

22)      Kaplan SA: The age related decline in testosterone is significantly exacerbated in obese men with the metabolic syndrome: what are the implications of this for the relatively high incidence of erectile dysfunction observed in these men? J Urol 175 (4): 692, 2006.

 

23)      Kaplan SA, Gonzalez RR, Ogiste J, Te AE: Combination of an alpha blocker, alfuzosin SR and a PDE – 5 inhibitor, sildenafil citrate is uperior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction. J Urol 175 (4): 1638, 2006.

 

24)      Kaplan SA, Fisch H, Berriman SJ, Saini R, Lee R, Te AE: Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms, sexual dysfunction, and        components of the metabolic syndrome. J Urol, 177 (4): 1508, 2007.

 

25)      Kaplan SA, Wilson TH: Association between BPH and the metabolic syndrome in the Reduce population. J Urol, 177 (4): 1548, 2007.

 

Back to topBack To Top